Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

InNexus Biotechnology, Xeris Pharmaceuticals announce drug delivery collaboration
January 2010
SHARING OPTIONS:

SCOTTSDALE, Ariz.InNexus Biotechnology Inc. and Xeris Pharmaceuticals Inc. announced in December a research collaboration in which the companies will pursue development of a potential subcutaneous delivery of InNexus' Dynamic Cross Linking (DXL) antibodies using XERIS' proprietary formulation-injection technologies. Financial terms of the collaboration were not released.

"We see a need for an improved delivery system for antibodies that enables self injection of these important therapeutic agents, by patients at home," says John Kinzell, CEO of Xeris. "Our delivery system addresses a number of major issues related to storing and administering antibodies, and is suitable for and could add value in both chronic and acute therapies."

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.